Table 1.

Published studies using L1CAM+ EVs as a source of biomarkers for various diseases.

Disease	Participants	Metabolites	References
Down syndrome (DS)	47 DS; 37 controls	Aβ42	Hamlett et al., 2016
		P-T181 TAU
		P-S396 TAU
Fetal alcohol syndrome (FAS)	20 pregnant women (10 EtOH users; 10 non-users)	HSF1	Goetzl L. et al., 2016
		BCL-XL
		REST
Preclinical prediction of AD	20 AD; 18 preAD (Cognition normal)	Aβ42	Abner et al., 2016
		P-T181 TAU
		Cathepsin D
		REST
		Neurogranin
AD	24 AD; 24 control	LRRP
		HSP1	Goetzl et al., 2015a
Preclinical prediction of AD	16 AD; 16 preAD	REST
AD	26 AD; 26 control	P-S312-IRS-1	Kapogiannis et al., 2015
Preclinical prediction of AD	22 AD; 22 preAD	P-panY- IRS-1
AD	26 AD; 26 control	Cathepsin D
		LAMP1	Goetzl et al., 2015b
		Ubiquitin
Preclinical prediction of AD	20 AD; 20 preAD	HSP70
AD	57 AD; 57 control	Aβ42 (0.001)
		P-T181 TAU	Fiandaca et al., 2015
Preclinical prediction of AD	24 AD; 24 preAD	P-S396 TAU
AD	24 AD; 28 control	Synaptotagmin	Goetzl et al., 2016a
		Synaptopodin
		Synaptophysin
		Neurogranin
		GAP43
AD	30 AD; 20 controls	REST	Winston et al., 2016
		Neurogranin
		Aβ42
		P-T181 TAU
		P-S396 TAU
PD	267 PD; 215 controls	α-Synuclein	Shi et al., 2014